Claims for Patent: 10,400,284

Summary for Patent: 10,400,284

Title:	Method for predicting responsiveness to a treatment with an EGFR inhibitor
Abstract:	The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
Inventor(s):	Rio Frio; Thomas (Paris, FR), Laurent-Puig; Pierre (Meudon, FR), Imbeaud; Sandrine (Vitry sur Seine, FR)
Assignee:	INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DESCARTES (Paris, FR)
Application Number:	14/360,311
Patent Claims:	1. A method for treating a patient affected with a cancer, which method comprises: (i) taking a biological sample from the patient affected with a cancer, (ii) measuring in vitro the expression level of hsa-miR-31-3p (SEQ ID NO:1) miRNA in the biological sample of said patient, (iii) determining whether the patient is likely to respond to an EGFR inhibitor based on the measured expression level of hsa-miR-31-3p from step (ii), and (iv) administering an EGFR inhibitor to said patient if the patient has been determined to be likely to respond to the EGFR inhibitor; wherein the patient is affected with a cancer selected from the group consisting of colorectal, breast, lung, ovarian, endometrial, thyroid, nasopharynx, prostate, head and neck, liver, kidney, pancreas, bladder, and brain cancer. 2. The method according to claim 1, further comprising, if the patient has been determined to be unlikely to respond to the EGFR inhibitor, a step (v) of administering an alternative anticancer treatment to the patient. 3. The method according to claim 1, wherein the patient is affected with a colorectal cancer. 4. The method according to claim 2, wherein the patient is affected with a colorectal cancer, and the alternative anticancer treatment administered to the patient is selected from: a. a VEGF inhibitor, advantageously in combination with FOLFOX or FOLFIRI chemotherapy, or b. 5-FU, optionally in combination with Mitomycin B. 5. The method according to claim 1, wherein the patient is affected with a breast cancer or a lung cancer. 6. The method according to claim 1, wherein the EGFR inhibitor is an anti-EGFR antibody. 7. The method according to claim 1, wherein the EGFR inhibitor is a tyrosine kinase EGFR inhibitor. 8. The method of claim 1, wherein the patient has a KRAS wild-type cancer. 9. The method of claim 1, wherein the biological sample is a tumor tissue biopsy or whole or part of a tumor surgical resection. 10. The method of claim 1, wherein the level of expression of the miRNA is determined by quantitative RT-PCR. 11. The method of claim 1, wherein the lower the level of expression of the miRNA is, the more likely the patient is to respond to the EGFR inhibitor treatment. 12. The method of claim 1, further comprising determining a prognostic score based on the expression level of the miRNA, wherein the prognostic score indicates whether the patient is likely to respond to the EGFR inhibitor. 13. The method of claim 12, wherein the prognostic score is of formula: Prognosis score=a*x+b, wherein: x is the logged expression level of hsa-miR-31-3p measured in the patient's sample, a and b are parameters that have been previously determined based on a pool of reference samples, and the patient is predicted as responding to the EGFR inhibitor if his/her prognosis score is lower than or equal to a threshold value c, and not responding to the EGFR inhibitor if its prognosis score is greater than threshold value c, wherein the value of c has been determined based on the same pool of reference samples. 14. The method of claim 13, wherein a, b and c are in the following ranges: a: (0.1; 0.25); b: (-2; -0.5);and c: (-0.11; -0.01). 15. The method of claim 1, further comprising determining the BRAF status of said patient, and calculating a composite score taking into account the expression level of hsa-miR-31-3p and the BRAF status, wherein the composite score indicates whether the patient is likely to respond to the EGFR inhibitor. 16. The method of claim 1, wherein: a) the cancer is colorectal cancer and the EGFR inhibitor is an anti-EGFR antibody; or b) the cancer is lung cancer and the EGFR inhibitor is a tyrosine kinase EGFR inhibitor. 17. The method of claim 1, wherein: a) the cancer is colorectal cancer and the EGFR inhibitor is an anti-EGFR antibody, wherein the anti-EGFR antibody is cetuximab or panitumumab; or b) the cancer is lung cancer, which is non small cell lung cancer (NSCLC) and the EGFR inhibitor is a tyrosine kinase EGFR inhibitor, wherein the tyrosine kinase EGFR inhibitor is Erlotinib, Gefitinib, or Lapatinib.

Details for Patent 10,400,284

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-11-25
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-11-25
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2031-11-25